Phaserx Inc. CEO Robert Overell told BioWorld the firm has paused its lead, preclinical effort in intracellular enzyme replacement therapy (iERT) as the search continues for "a strategic transaction, including a potential merger" to advance the pipeline. "The goal is to get this technology and these programs into the hands of a group who can adequately capitalize it and capitalize on it," he said.